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Genetic diff erences among humans range from very 
common (minor allele frequency (MAF) nearly 0.5) to 
the very rare (MAF <0.001). In the pre-genomic era, the 
hunt for disease-causing variants was restricted to rare 
alleles of high penetrance, and required a careful analysis 
of the mode of inheritance. With the advent of high-
throughput technologies, it became possible to perform 
genome-wide association studies on tens of thousands of 
people and to examine hundreds of thousands of 
common SNPs. It was therefore notable that a pervasive 
opinion at this year’s meeting, articulated by keynote 
speaker Richard Gibbs (Baylor College of Medicine, USA) 
among others, was that we are clearly beyond the 
genome-wide association study, and that common SNPs, 
if they have any value for health, were not worth talking 
about on this occasion. Th e search is on once again for 
rare variants, only this time we wield the ever-increasing 
power of modern genomics.
Bioinformatics for the masses (masses of data and 
masses of users)
Finding rare variants is not easy. Th e fi rst day focused on 
the formidable bioinformatics challenges. Although the 
current capabilities to fi nd SNPs in short-read sequences 
are robust, accurate calling of compound SNPs and the 
phasing of variants on chromosomes remains elusive. An 
important challenge today is identifying multinucleotide 
polymorphisms, such as small insertions and deletions 
(indels), because only part of an indel-spanning read will 
map perfectly to the reference genome (Gabor Marth, 
Boston College, USA). A related challenge is repeated 
sequences: the ‘dark matter’ that makes up most of the 
human genome and the Achilles heel of short-read 
sequencing. One solution is to include long, although 
currently error-prone, reads from platforms such as 
PacBio in such a way that the combined data reduce the 
errors and span the gaps (Mike Schatz, Cold Spring 
Harbor Laboratories, USA).
Th e challenge for tomorrow is robust identifi cation of 
copy number variants, important for medicine but 
currently diffi  cult to characterize with precision using 
automated, unsupervised methods. Such methods are the 
goal of the modern tool developer. To get informatics 
tools out of the hands of data analysts and into the hands 
of data generators will require the tools to be easy, robust 
and reproducible. Th e session ended with a bioinformatic 
challenge for the audience. Conference attendees were 
challenged to identify a famous quote that had been 
encoded as DNA sequence and inserted into an unknown 
genome, which itself required de novo assembly from a 
set of short reads. As a testament to what can be accom-
plished with today’s skills and tools, the prize was won in 
under an hour.
What to do about the many rare variants
Clearly some rare variants have a large eff ect on disease. 
Th e problem is there are too many rare variants. Th e 
number of SNPs with MAF 0.001 to 0.5 has plateaued at 
around 36 million, but the number of SNPs found with an 
MAF  <0.001 is soaring. Speakers on the second day 
grappled with the uncertainty and implications of fi nding 
such variants on a medical, ethical and legal level. Th e 
observation that about 500 missense mutations and 100 
loss-of-function mutations exist in apparently healthy 
people raises important ethical questions about returning 
this information to patients, especially in the frequent 
case that such alleles are incidental to the patient’s 
original health concern. An important concept to emerge 
was that better predictions of a variant’s health conse-
quence could be made by incorporating additional know-
ledge or ‘priors’, such as family history, known protein 
and gene interaction networks, gene expression data, and 
comparison with genomes of healthy individuals (Ben 
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Raphael, Brown University, USA; Josh Stuart, University 
of California Santa Cruz, USA; Lynn Jorde, University of 
Utah, USA; Daniel MacArthur, Massachusetts General 
Hospital, USA; John Carpten, TGen, USA).
Some portion of variant calls will be wrong because of 
wrong annotations, wrong priors (including the use of 
healthy controls that were not actually healthy), errors in 
sequencing, and errors due to multiple testing (Isaac 
Kohane, Harvard Medical School and Children’s 
Hospital, USA; James Lupski, Baylor College of Medicine, 
USA). Several strategies were put forward to guard 
against such errors in the clinic. Leslie Biesecker 
(National Human Genome Research Institute, USA) 
suggested a provocative paradigm shift from studying the 
genetics of people with known disease to studying the 
diseases of people with known genetics. Sharon Plon 
(Baylor College of Medicine, USA) and others cited the 
use of genetics review panels, not simply bioinformatics 
pipelines, to decide what information rises to the rigor of 
clinical disclosure. Some clinical testing paradigms avoid 
the time, cost, errors and ethics of large-scale multiple 
testing by focusing on only small panels of ‘actionable’ 
variants (estimated to encompass as few as 47 to 57 
clinically actionable genes; Elizabeth Worthey, Medical 
College of Wisconsin, USA; Yost Shawn, University of 
California San Diego, USA). Database annotations are 
improving (newer ones are improving faster than the 
older, more established ones), and an interesting sugges-
tion was made that variants in databases should include 
fields for ‘user feedback’. Gibbs closed the session by 
forecasting that genomics in the next 10 years would see 
the most application in Mendelian disorders, cancer and 
technology development, and less in studying complex 
diseases or healthy adults.
Beyond Mendel: other uses of the genome to 
improve public health
The theme of the third day was the use of genomics to 
study more dynamic processes. Most cells of the body 
contain the same genome, but they assume different 
functional roles because of the genes they transcribe. 
Gene transcription in each cell is controlled by the 
epigenome, and each cell type contains a different epi-
genome. Two talks discussed what information trans crip-
tion factors use to determine which genes they regulate 
(Frank Pugh, Penn State University, USA), and how the 
three-dimensional architecture of the genome deter-
mines which genes can interact (Job Dekker University of 
Massachusetts Medical School, USA). Other talks 
described changes in DNA methylation patterns that 
were dependent on factors such as age, tissue, disease 
states such as cancer, and the location within the three-
dimensional architecture of the genome (Peter Laird, 
University of Southern California, USA; Vardhman 
Rakyan, Barts and The London School of Medicine and 
Dentistry, UK). In many cases, the effects of these 
changes on gene expression were unclear. However, in 
some cases the changes had unambiguous consequences 
for gene expression and could therefore be predictive of, 
for example, cancer phenotypes.
Cancer is unlike most other diseases in that the genome 
itself is dynamic and changes during disease progression. 
Genomics can provide a window on the clonality of 
cancer lineages and the heterogeneity within tumors 
(Samuel Aparicio, BC Cancer Research Center, Canada; 
Arend Sidow, Stanford University, USA). These intensive 
genomics and systems biology efforts are also being 
applied in the treatment of cancer. Genome-wide 
methods were used to identify the right target, choose 
the right drug, and will ultimately be used to find the 
right patients (those with compatible genetics). A critical 
component of these efforts was the assay system. In 
developing inhibitors to the oncoprotein NRAS in 
melanoma, Lynda Chin (MD Anderson Cancer Center, 
USA) took the perspective that cells in a real tumor 
behave quite differently from cells in a culture dish or 
xenograft. The most informative pre-clinical assays need 
to recapitulate the many facets of cancer in a person, 
such as a mouse model in which tumors arise endo-
genously from an inducible NRas gene. On the opposite 
end of the spectrum, keynote speaker Stuart Schreiber 
(Broad Institute of Harvard and MIT, USA) used cancer 
cell lines, but a lot of them. Nine hundred cell lines that 
had been carefully characterized genetically and trans-
crip tionally were assayed to identify factors controlling 
their susceptibility or resistance to 480 chemical com-
pounds at 16 different concentrations. A subset of 
interesting cases was further screened against a library of 
30,000 compounds. From these studies emerged a wealth 
of provocative hypotheses. Although many advances 
were reported throughout the conference, these latter 
talks were perhaps the most inspiring in that they showed 
how genomic information could be used not just to 
understand or diagnose disease but to actually improve 
upon the treatments of today, truly moving us towards 
the goals that lie beyond the genome.
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